Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $8.06
Previous CloseN/A
Volume1.36M
Average Volume (3M)5.73M
Market Cap
$940.27M
Enterprise Value$990.40M
Total Cash (Recent Filing)$213.95M
Total Debt (Recent Filing)$155.11M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Jul 31, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding239,255,220
10 Day Avg. Volume3,426,305
30 Day Avg. Volume5,732,182
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)5.93
Price to Sales (P/S)0.00
P/FCF Ratio-17.77
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit3.22
Enterprise Value/Ebitda-6.65
Forecast
1Y Price Target
$11.11Price Target Upside201.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Ardelyx News
PremiumCompany Announcements
Ardelyx Inc Reports Strong Growth Amid Challenges
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityArdelyx maintained a strong cash position of ~$214M, providing flexibility for continued commercial investment and pipeline opportunities.
Market UptakeTenapanor (Ibsrela) for the treatment of IBS-C was launched in the U.S. and continues to see favorable uptake.
Sales PotentialAnticipated $750MM in peak U.S. sales for the Ibsrela opportunity and $660MM for the Xphozah opportunity.
Bears Say
Coverage ChallengesXphozah Q1 revenue was impacted by the loss of Medicare D coverage due to oral only phosphate drugs being included in the ESRD bundle.
Litigation RisksLitigation against CMS presents uncertainty, with the outcome and date for oral arguments still pending.
Sales PerformanceRevenue forecasts for Ibsrela and Xphozah were incrementally lowered to reflect the weaker 1Q performance.
Ownership Overview
3.34% Insiders
23.00% Mutual Funds
6.90% Other Institutional Investors
54.09% Public Companies and Individual Investors
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $8.06 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $940.27M.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Jul 31, 2025 which is in 55 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on May 01, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.112 by -$0.058.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.12.
How many shares outstanding does Ardelyx have?
Ardelyx has 239,255,220 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.112. Following the earnings report the stock price went down -24.497%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.11 (201.08% Upside)
$11.11 (201.08% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 99.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.28%
12-Months-Change
Fundamentals
Return on Equity
-36.26%
Trailing 12-Months
Asset Growth
19.81%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights significant revenue growth and strategic progress with IBSRELA and XPHOZAH. However, challenges such as market contractions, Medicare disruptions, and increased expenses were noted. The company's strong cash position and milestone achievement in China provide additional positives.Read More>ARDX Stock 12 Month Forecast
Average Price Target
$11.11
▲(201.08%Upside)
Technical Analysis
Celldex
―
MiMedx Group
―
Ocular Therapeutix
―
Aurinia Pharmaceuticals
―
Liquidia Technologies
―